Corporate Lawsuits Surge Over Misstatements & Delays
A wave of securities fraud class action lawsuits suggests heightened legal scrutiny on corporate disclosures. Recent targets include BellRing Brands for alleged inventory issues, Ardent Health over collections problems, and uniQure N.V. following an FDA approval delay.
The uptick in securities litigation reflects a broader trend, with 225 new securities class action lawsuits filed in federal and state courts in 2024, an increase from 215 in 2023. This surge is primarily driven by a record high number of cases asserting claims under Section 10(b) of the Securities Exchange Act of 1934. In the case of BellRing Brands, the lawsuit alleges that the company's reported sales growth was misleadingly attributed to "organic growth" and "strong macro tailwinds," when it was actually the result of key customers stockpiling inventory. This alleged misrepresentation concealed eroding market share, and when the company later revealed a "mid-single-digit headwind" from retailers reducing their supply, the stock price fell 19% on May 6, 2025, and then another 33% on August 5, 2025, after narrowing its fiscal year guidance. The lawsuit against Ardent Health centers on its accounting practices, specifically how it determined the collectability of its accounts receivable. The company is accused of delaying the recognition of losses on uncollectable accounts. On November 12, 2025, Ardent disclosed a $43 million decrease in quarterly revenue due to revised collectability assessments, which was followed by a nearly 34% drop in its share price the next day. For uniQure N.V., the legal action stems from its communications regarding the FDA approval pathway for its Huntington's Disease drug candidate. The lawsuit alleges the company was not transparent about the FDA's full approval of its Pivotal Study design. On November 3, 2025, uniQure announced that the timing for its Biologics License Application was unclear, leading to a 49% plunge in its stock price. These legal challenges often have a significant and immediate financial impact. Studies have shown that the announcement of a securities class action lawsuit can lead to an average abnormal return drop of 12.3% for a company's stock in the 20-day window surrounding the filing. The reputational damage and resulting loss in market value can far exceed any potential settlement costs. A handful of law firms are particularly active in this space. For instance, firms like The Rosen Law Firm, Kahn Swick & Foti, and Bleichmar Fonti & Auld are frequently involved in filing these types of securities fraud class actions on behalf of investors. In 2024, just four plaintiff law firms were responsible for 76% of the core federal filings that referenced reports from short sellers. The cases against BellRing and Ardent are pending in the U.S. District Court for the Southern District of New York and the Middle District of Tennessee, respectively. Investors in these companies have deadlines in March 2026 to file for lead plaintiff status. The uniQure case is also pending, with an April 2026 deadline for lead plaintiff applications.
